Menlo Therapeutics Inc. (MNLO) News
Filter MNLO News Items
MNLO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MNLO News From Around the Web
Below are the latest news stories about Menlo Therapeutics Inc that investors may wish to consider to help them evaluate MNLO as an investment opportunity.
What You Need To Know About Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Investor CompositionA look at the shareholders of Menlo Therapeutics Inc. (NASDAQ:MNLO) can tell us which group is most powerful... |
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in SeptemberBRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment Conference Date:September 14 Time:2:30pm Eastern Time Webcast:https://wsw.com/webcast/hcw7/vyne/1630674 Cantor Fitzgerald Virtual Global Healthcare Conference Date:September 16 Time:10:00am Eastern Time Webcast:https://www.webcaster4.com/Webcast/Page/2495/37311 The Cantor Fitzgerald presentation will take the form of a “Fireside Chat” with analyst Louise Chen.About VYNE Therapeutics Inc. VYNE Thera... |
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE TherapeuticsVYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE". The name and ticker symbol changes are effective as of the opening of trading today, September 8, 2020. |
Menlo Therapeutics Announces Corporate Name Change to VYNE TherapeuticsCompany will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc. (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “VYNE”. The name and ticker change will be effective at the opening of trading, Tuesday, September 8, 2020. In addition, VYNE Therapeutics will ring the Nasdaq closing bell on September 8, at 4:00 PM ET. “Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our ... |
Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call TranscriptMenlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Sadia Rahman... |
Hedge Funds Have Never Been This Bullish On Menlo Therapeutics Inc. (MNLO)Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […] |
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth AheadSince January of this year, shares of Menlo Therapeutics (MNLO) (formerly Foamix) have been cut by roughly two-thirds, given the fallout of the Coronavirus pandemic, as well as the lackluster result of the merger between Foamix and Menlo to form the newly combined company. With the failure of serlopitant, the... |
Menlo Therapeutics drops 17% after pricing equity offeringMenlo Therapeutics (MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500.Underwriters' over-allotment is an additional 4,057,500 shares.Closing date is June 9.Shares are down 17% premarket.... |
Why Menlo Therapeutics Stock Sank TodayThe decline came after the company announced the pricing of a stock offering Friday morning. The number of shares being offered represents nearly 20% of the total number of outstanding shares. Stocks usually fall on public offerings because the value of existing shares is diluted. |
Menlo Therapeutics Announces Pricing of Offering of Common StockMenlo Therapeutics Inc. (“Menlo”) (MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 27,050,000 shares of common stock at a price to the public of $1.85 per share. All of the shares of common stock to be sold in the offering will be offered by Menlo. In addition, Menlo has granted the underwriters a 30-day option to purchase up to an additional 4,057,500 shares of its common stock. |